Zobrazeno 1 - 10
of 947
pro vyhledávání: '"Perrais, M."'
Autor:
Perrais M; Unit of Forensic Chemistry and Toxicology, 658784 University Centre of Legal Medicine Lausanne-Geneva , Geneva University Hospital and University of Geneva, Geneva, Switzerland.; Faculty Unit of Toxicology, 658784 University Centre of Legal Medicine Lausanne-Geneva , Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Trächsel B; 569258 Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Lenglet S; Unit of Forensic Chemistry and Toxicology, 658784 University Centre of Legal Medicine Lausanne-Geneva , Geneva University Hospital and University of Geneva, Geneva, Switzerland., Pruijm M; Service of Nephrology, Lausanne University Hospitals and University of Lausanne, Lausanne, Switzerland., Ponte B; Division of Nephrology and Hypertension, Geneva University Hospitals, Geneva, Switzerland., Vogt B; 27252 University Department of Nephrology and Hypertension, Inselspital, University Hospital Bern , Bern, Switzerland., Augsburger M; Unit of Forensic Chemistry and Toxicology, 658784 University Centre of Legal Medicine Lausanne-Geneva , Geneva University Hospital and University of Geneva, Geneva, Switzerland., Rousson V; 569258 Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Bochud M; 569258 Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland., Thomas A; Unit of Forensic Chemistry and Toxicology, 658784 University Centre of Legal Medicine Lausanne-Geneva , Geneva University Hospital and University of Geneva, Geneva, Switzerland.; Faculty Unit of Toxicology, 658784 University Centre of Legal Medicine Lausanne-Geneva , Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Publikováno v:
Clinical chemistry and laboratory medicine [Clin Chem Lab Med] 2024 Apr 22; Vol. 62 (11), pp. 2242-2255. Date of Electronic Publication: 2024 Apr 22 (Print Publication: 2024).
Autor:
Bourdon E; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Swierczewski T; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Goujon M; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Boukrout N; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Fellah S; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Van der Hauwaert C; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Larrue R; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.; CHU Lille, Service de Toxicologie et Génopathies, F-59000 Lille, France., Lefebvre B; Univ. Lille, CNRS, Inserm, CHU Lille, UMR-S1172, Neuroscience & Cognition, Alzheimer & Tauopathies, F-59000 Lille, France., Van Seuningen I; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Cauffiez C; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Pottier N; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.; Univ. Lille, CNRS, Inserm, CHU Lille, UMR-S1172, Neuroscience & Cognition, Alzheimer & Tauopathies, F-59000 Lille, France., Perrais M; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.
Publikováno v:
Cancers [Cancers (Basel)] 2024 Jan 17; Vol. 16 (2). Date of Electronic Publication: 2024 Jan 17.
Autor:
Larrue R; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France. romain.larrue@chu-lille.fr.; Service de Toxicologie et Génopathies, CHU Lille, F-59000, Lille, France. romain.larrue@chu-lille.fr., Fellah S; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Hennart B; Service de Toxicologie et Génopathies, CHU Lille, F-59000, Lille, France., Sabaouni N; Service de Toxicologie et Génopathies, CHU Lille, F-59000, Lille, France., Boukrout N; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Van der Hauwaert C; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Delage C; Service de Toxicologie et Génopathies, CHU Lille, F-59000, Lille, France., Cheok M; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Perrais M; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Cauffiez C; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Allorge D; Service de Toxicologie et Génopathies, CHU Lille, F-59000, Lille, France., Pottier N; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Service de Toxicologie et Génopathies, CHU Lille, F-59000, Lille, France.
Publikováno v:
The pharmacogenomics journal [Pharmacogenomics J] 2024 Jan 12; Vol. 24 (1), pp. 1. Date of Electronic Publication: 2024 Jan 12.
Autor:
Larrue R; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France., Fellah S; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France., Boukrout N; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France., De Sousa C; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France., Lemaire J; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France., Leboeuf C; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France., Goujon M; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France., Perrais M; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France., Mari B; Université Côte d'Azur, CNRS UMR7275, IPMC, FHU-OncoAge, IHU RespiERA, 06560, Valbonne, France., Cauffiez C; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France., Pottier N; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France., Van der Hauwaert C; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France. cynthia.vanderhauwaert@inserm.fr.
Publikováno v:
Cell death & disease [Cell Death Dis] 2023 Sep 13; Vol. 14 (9), pp. 603. Date of Electronic Publication: 2023 Sep 13.
Autor:
Equey A; Center for Primary Care and Public Health (Unisanté), University of Lausanne, Route de La Corniche 10, 1010, Lausanne, Switzerland., Berger MM; Service of Adult Intensive Care, Lausanne University Hospital (CHUV), Lausanne, Switzerland. Electronic address: mette.berger@unil.ch., Gonseth-Nusslé S; Center for Primary Care and Public Health (Unisanté), University of Lausanne, Route de La Corniche 10, 1010, Lausanne, Switzerland., Augsburger M; Forensic Toxicology and Chemistry Unit, University Centre of Legal Medicine, Lausanne-Geneva, Lausanne University Hospital and University of Lausanne - Geneva University Hospital and University of Geneva, Lausanne-Geneva, Switzerland., Rezzi S; Swiss Nutrition and Health Foundation, Épalinges, Switzerland., Hodgson ACC; Swiss Nutrition and Health Foundation, Épalinges, Switzerland., Estoppey S; Center for Primary Care and Public Health (Unisanté), University of Lausanne, Route de La Corniche 10, 1010, Lausanne, Switzerland., Pantaleo G; Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Pellaton C; Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Perrais M; Forensic Toxicology and Chemistry Unit, University Centre of Legal Medicine, Lausanne-Geneva, Lausanne University Hospital and University of Lausanne - Geneva University Hospital and University of Geneva, Lausanne-Geneva, Switzerland., Lenglet S; Forensic Toxicology and Chemistry Unit, University Centre of Legal Medicine, Lausanne-Geneva, Lausanne University Hospital and University of Lausanne - Geneva University Hospital and University of Geneva, Lausanne-Geneva, Switzerland., Rousson V; Center for Primary Care and Public Health (Unisanté), University of Lausanne, Route de La Corniche 10, 1010, Lausanne, Switzerland., D'Acremont V; Center for Primary Care and Public Health (Unisanté), University of Lausanne, Route de La Corniche 10, 1010, Lausanne, Switzerland., Bochud M; Center for Primary Care and Public Health (Unisanté), University of Lausanne, Route de La Corniche 10, 1010, Lausanne, Switzerland.
Publikováno v:
Clinical nutrition (Edinburgh, Scotland) [Clin Nutr] 2023 Jun; Vol. 42 (6), pp. 972-986. Date of Electronic Publication: 2023 Apr 18.
Autor:
Equey, A., Berger, M.M., Gonseth-Nusslé, S., Augsburger, M., Rezzi, S., Hodgson, A.C., Estoppey, S., Pantaleo, G., Pellaton, C., Perrais, M., Lenglet, S., Rousson, V., D'Acremont, V., Bochud, M.
Publikováno v:
In Clinical Nutrition ESPEN December 2023 58:690-691
Autor:
Perrais M; Unit of Forensic Chemistry and Toxicology, University Centre of Legal Medicine Lausanne-Geneva, Geneva University Hospital and University of Geneva, Rue Michel-Servet 1, Geneva 4 CH-1211, Switzerland.; Faculty Unit of Toxicology, University Centre of Legal Medicine Lausanne-Geneva, Lausanne University Hospital and University of Lausanne, Chemin de la Vulliette 4, Lausanne 25 CH-1000, Switzerland., Thomas A; Unit of Forensic Chemistry and Toxicology, University Centre of Legal Medicine Lausanne-Geneva, Geneva University Hospital and University of Geneva, Rue Michel-Servet 1, Geneva 4 CH-1211, Switzerland.; Faculty Unit of Toxicology, University Centre of Legal Medicine Lausanne-Geneva, Lausanne University Hospital and University of Lausanne, Chemin de la Vulliette 4, Lausanne 25 CH-1000, Switzerland., Augsburger M; Unit of Forensic Chemistry and Toxicology, University Centre of Legal Medicine Lausanne-Geneva, Geneva University Hospital and University of Geneva, Rue Michel-Servet 1, Geneva 4 CH-1211, Switzerland., Lenglet S; Unit of Forensic Chemistry and Toxicology, University Centre of Legal Medicine Lausanne-Geneva, Geneva University Hospital and University of Geneva, Rue Michel-Servet 1, Geneva 4 CH-1211, Switzerland.
Publikováno v:
Journal of analytical toxicology [J Anal Toxicol] 2023 Mar 21; Vol. 47 (2), pp. 175-181.
Autor:
Dewaeles E; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.; University of Lille, INSERM, CHU Lille, UMR-S1172 LilNCog, Lille Neuroscience and Cognition, Lille, France., Carvalho K; University of Lille, INSERM, CHU Lille, UMR-S1172 LilNCog, Lille Neuroscience and Cognition, Lille, France.; Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France., Fellah S; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Sim J; Department of Physiology, Michigan State University, East Lansing, Michigan, USA.; Cell and Molecular Biology Graduate program, Michigan State University, East Lansing, Michigan, USA., Boukrout N; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Caillierez R; University of Lille, INSERM, CHU Lille, UMR-S1172 LilNCog, Lille Neuroscience and Cognition, Lille, France.; Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France., Ramakrishnan H; Department of Physiology, Michigan State University, East Lansing, Michigan, USA., Van der Hauwaert C; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.; CHU Lille, Département de la Recherche en Santé, Lille, France., Vijaya Shankara J; University of Lille, INSERM, CHU Lille, UMR-S1172 LilNCog, Lille Neuroscience and Cognition, Lille, France.; Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France., Martin N; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Massri N; Department of Physiology, Michigan State University, East Lansing, Michigan, USA.; Cell and Molecular Biology Graduate program, Michigan State University, East Lansing, Michigan, USA., Launay A; University of Lille, INSERM, CHU Lille, UMR-S1172 LilNCog, Lille Neuroscience and Cognition, Lille, France.; Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France., Folger JK; Department of Physiology, Michigan State University, East Lansing, Michigan, USA., de Schutter C; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Larrue R; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.; CHU Lille, Service de Toxicologie et Génopathies, Lille, France., Loison I; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Goujon M; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Jung M; University of Strasbourg, CNRS UMR 7104, INSERM U1258 - GenomEast Platform - IGBMC - Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France., Le Gras S; University of Strasbourg, CNRS UMR 7104, INSERM U1258 - GenomEast Platform - IGBMC - Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France., Gomez-Murcia V; University of Lille, INSERM, CHU Lille, UMR-S1172 LilNCog, Lille Neuroscience and Cognition, Lille, France.; Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France., Faivre E; University of Lille, INSERM, CHU Lille, UMR-S1172 LilNCog, Lille Neuroscience and Cognition, Lille, France.; Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France., Lemaire J; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Garat A; CHU Lille, Service de Toxicologie et Génopathies, Lille, France.; University of Lille, CHU Lille, Institut Pasteur de Lille, ULR 4483, IMPact de l'Environnement Chimique sur la Santé Humaine (IMPECS), Lille, France., Beauval N; CHU Lille, Service de Toxicologie et Génopathies, Lille, France.; University of Lille, CHU Lille, Institut Pasteur de Lille, ULR 4483, IMPact de l'Environnement Chimique sur la Santé Humaine (IMPECS), Lille, France., Maboudou P; CHU Lille, Service de Biochimie Automatisée, Protéines et Biologie Prédictive, Lille, France., Gnemmi V; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.; CHU Lille, Service d'Anatomopathologie, Lille, France., Gibier JB; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.; CHU Lille, Service d'Anatomopathologie, Lille, France., Buée L; University of Lille, INSERM, CHU Lille, UMR-S1172 LilNCog, Lille Neuroscience and Cognition, Lille, France.; Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France., Abbadie C; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Glowacki F; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.; CHU Lille, Service de Néphrologie, Lille, France., Pottier N; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.; CHU Lille, Service de Toxicologie et Génopathies, Lille, France., Perrais M; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France., Cunha RA; CNC, Center for Neuroscience and Cell Biology, University of Coimbra, Rua Larga, Faculty of Medicine Building-Polo 1, Coimbra, Portugal.; Faculty of Medicine, University of Coimbra, Coimbra, Portugal., Annicotte JS; University of Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, INSERM U1283-UMR8199 - EGID, Lille, France.; University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France., Laumet G; Department of Physiology, Michigan State University, East Lansing, Michigan, USA., Blum D; University of Lille, INSERM, CHU Lille, UMR-S1172 LilNCog, Lille Neuroscience and Cognition, Lille, France.; Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France., Cauffiez C; University of Lille, INSERM, CNRS, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.
Publikováno v:
The Journal of clinical investigation [J Clin Invest] 2022 Nov 15; Vol. 132 (22). Date of Electronic Publication: 2022 Nov 15.
Autor:
Larrue R; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Fellah S; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Van der Hauwaert C; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.; CHU Lille, Département de la Recherche en Santé, F-59000 Lille, France., Hennino MF; CH Valenciennes, Service de Néphrologie, F-59300 Valenciennes, France., Perrais M; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Lionet A; CHU Lille, Service de Néphrologie, F-59000 Lille, France., Glowacki F; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.; CHU Lille, Service de Néphrologie, F-59000 Lille, France., Pottier N; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Cauffiez C; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.
Publikováno v:
Cells [Cells] 2022 Nov 07; Vol. 11 (21). Date of Electronic Publication: 2022 Nov 07.
Autor:
Lemaire, J., Van der Hauwaert, C., Savary, G., Dewaeles, E., Perrais, M., Lo Guidice, J. M., Pottier, N., Glowacki, F., Cauffiez, C.
Publikováno v:
International Journal of Toxicology (Sage); Mar/Apr2020, Vol. 39 Issue 2, p103-114, 12p